

Common diabetes drug not linked to shortterm risk of pancreatic cancer

September 5 2014, by Mark Derewicz



John Buse, MD, PhD, UNC School of Medicine

(Medical Xpress)—Researchers at the UNC Gillings School of Global Public Health and the UNC School of Medicine have found that a popular class of diabetes medications called DPP-4 inhibitors does not increase the short-term risk of pancreatic cancer, as was previously reported by other researchers.

"Our research shows that short-term use of DPP-4 inhibitors in older diabetes <u>patients</u> does not increase their risk for pancreatic cancer," said John Buse, MD, PhD, director of the Diabetes Care Center at UNC and co-author of the paper in the current issue of the journal Diabetes, Obesity and Metabolism. "However, we just cannot address the long-



term safety, yet. There are just not enough people who have taken the drug for many years."

DPP-4 inhibitors came on the market in 2006. Since then, these drugs have become some of the most commonly prescribed <u>diabetes</u> <u>medications</u>, primarily because they often cause fewer side effects compared to other <u>diabetes</u> treatments.

But in 2009, the Food and Drug Administration issued a safety warning for DPP-4 inhibitors following reports of acute pancreatitis in patients. Subsequent to that warning, analysis of the FDA Adverse Events Reporting database and autopsy studies suggested that patients who had taken DPP-4 inhibitors faced an increased risk of pancreatic cancer. However, other researchers were critical of the studies, saying the research had been limited by study design, small numbers of patients involved, and the absence of key information needed to make the claim that DPP-4 inhibitors were linked to short-term risk of pancreatic cancer.

Using a more advanced study design, UNC researchers led by Mugdha Gokhale, MS, research assistant at UNC Gillings School of Global Public Health, compared the rate of pancreatic cancer diagnoses among a random sample of Medicare beneficiaries. Some patients had taken DPP-4 inhibitors; others had taken two different but also commonly prescribed medications – sulfonylureas and thiazolidinediones. Then researchers compared the rate of pancreatic cancer diagnoses among the two groups of patients and found no increased risk of <u>pancreatic cancer</u> among patients who had used DPP-4 inhibitors. The study examined realworld treatment patterns and used a variety of well-validated research techniques to minimize confounding problems that can occur in such observational studies.

This population-based study, which mimicked clinical treatment



decisions, indicated that cancer risk among older diabetic patients using DPP-4 drugs does not increase even in the second year of drug exposure. However, longer treatment periods have not been studied, nor have long-term risks. But Buse said that the results should reassure patients and providers regarding the safety of DPP-4 <u>inhibitors</u> for older patients.

More information: "Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study." Gokhale M, Buse JB, Gray CL, Pate V, Marquis MA, Stürmer T. *Diabetes Obes Metab.* 2014 Aug 11. <u>DOI:</u> <u>10.1111/dom.12379</u>. [Epub ahead of print]

Provided by University of North Carolina at Chapel Hill School of Medicine

Citation: Common diabetes drug not linked to short-term risk of pancreatic cancer (2014, September 5) retrieved 5 May 2024 from <u>https://medicalxpress.com/news/2014-09-common-diabetes-drug-linked-short-term.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.